Coverage
-
October 29, 2018
A Pennsylvania federal judge Monday dismissed litigation by Watson Laboratories Inc. and Allergan Finance LLC that sought the court's declaration that the Federal Trade Commission lacks authority to bring a pay-for-delay generic drug suit, while blasting the commission's decision to refile in California as an act of "apparent forum shopping."
9 other articles on this case.
View all »